ReviewDiagnostics (Basel, Switzerland)2021
The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer's Disease and Parkinson's Disease.
Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 45 citations in OpenAlex.
- Body Fluid-based Biomarkers for Cognitive Impairment in Parkinson's Disease.Annals of neurosciences · 2026Review
- Sex-Specific Salivary Biochemical Composition in a Healthy Population.International journal of molecular sciences · 2026Article
- Advances in biomarkers for diagnosing and prognosticating disorders of consciousness.Frontiers in neuroscience · 2026Review
- Shotgun metagenomic analysis of the tongue-coating microbiome reveals oral microbes and their functions in older adults with dementia.Journal of oral microbiology · 2026Article
- TLRs and NLRs modulate oral microbiome involvement in Alzheimer's disease.Metabolic brain disease · 2025Review
- Micro- and nanoscale biosensing technologies for early diagnosis of Parkinson's disease.Mikrochimica acta · 2025Review
- Advancing Parkinson's diagnosis: seed amplification assay for α-synuclein detection in minimally invasive samples.Molecular and cellular biochemistry · 2025Review
- Establishing age-group specific reference intervals of human salivary proteome and its preliminary application for epilepsy diagnosis.Science China. Life sciences · 2025Article
- Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson's disease.Frontiers in neurology · 2025Review
- Prospecting salivary tau as a diagnostic for Alzheimer's type dementia.Dementia & neuropsychologia · 2025Article
- The Role of Oral Biomarkers in the Assessment of Noncommunicable Diseases.Diagnostics (Basel, Switzerland) · 2024Review
- Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for Clinicians.Neurology and therapy · 2024Article
- Neurotoxic stimulation alters prosaposin levels in the salivary systems of rats.Cell and tissue research · 2024Article
- Alzheimer's disease: a review on the current trends of the effective diagnosis and therapeutics.Frontiers in aging neuroscience · 2024Review
- Liquid Biopsy in Neurological Diseases.Cells · 2023Review
- Salivary biomarkers: novel noninvasive tools to diagnose chronic inflammation.International journal of oral science · 2023Review
- Dysphagia in Parkinson Disease: Part I - Pathophysiology and Diagnostic Practices.Current physical medicine and rehabilitation reports · 2023Article
- Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease:IBRO neuroscience reports · 2023Article
- Recent Developments in the Design and Fabrication of Electrochemical Biosensors Using Functional Materials and Molecules.Biosensors · 2023Review
- Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases.Translational neurodegeneration · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many neurodegenerative diseases present with progressive neuronal degeneration, which can lead to cognitive and motor impairment. Early screening and diagnosis of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) are necessary to begin treatment before the onset of clinical symptoms and slow down the progression of the disease. Biomarkers have shown great potential as a diagnostic tool in the early diagnosis of many diseases, including AD and PD. However, screening for these biomarkers usually includes invasive, complex and expensive methods such as cerebrospinal fluid (CSF) sampling through a lumbar puncture. Researchers are continuously seeking to find a simpler and more reliable diagnostic tool that would be less invasive than CSF sampling. Saliva has been studied as a potential biological fluid that could be used in the diagnosis and early screening of neurodegenerative diseases. This review aims to provide an insight into the current literature concerning salivary biomarkers used in the diagnosis of AD and PD. The most commonly studied salivary biomarkers in AD are β-amyloid
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.